CoreCap Advisors’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
Other funds holding CRL
CoreCap Advisors's CRL Position: Q3 2026 in Review
CoreCap Advisors increased its Charles River Laboratories (CRL) stake by 94% in Q3 2026, buying an estimated $7.64K and bringing the position to 60 shares worth $17.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1846.
CoreCap Advisors first reported a position in CRL in Q4 2021 and has held it in 13 quarters since. The position peaked at $42K in Q4 2021. 104 funds tracked by Wall St. Rank hold CRL as of Q3 2026.
- CoreCap Advisors held 60 shares of Charles River Laboratories worth $17.7K as of Q3 2026.
- CoreCap Advisors bought 29 Charles River Laboratories shares in Q3 2026, an estimated $7.64K.
- Charles River Laboratories made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #1846 holding.
- CoreCap Advisors first reported a position in Charles River Laboratories in Q4 2021 and has held it in 13 quarters since.
- CoreCap Advisors's Charles River Laboratories position peaked at $42K in Q4 2021.
- 104 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.
Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.